These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

143 related articles for article (PubMed ID: 19200455)

  • 1. Molecular perspectives on the non-responder phenomenon.
    Jackson DB
    Drug Discov Today; 2009 Apr; 14(7-8):373-9. PubMed ID: 19200455
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Clinical and economic impact of the nonresponder phenomenon--implications for systems based discovery.
    Jackson DB
    Drug Discov Today; 2009 Apr; 14(7-8):380-5. PubMed ID: 19200855
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Drug resistance in cancer - searching for mechanisms, markers and therapeutic agents.
    O'Connor R; Clynes M; Dowling P; O'Donovan N; O'Driscoll L
    Expert Opin Drug Metab Toxicol; 2007 Dec; 3(6):805-17. PubMed ID: 18028026
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Molecular-targeted therapies: lessons from years of clinical development.
    Rosa DD; Ismael G; Lago LD; Awada A
    Cancer Treat Rev; 2008 Feb; 34(1):61-80. PubMed ID: 17826917
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Molecular targeted therapy for cancer].
    Sone S; Kuramoto T; Sato S; Mitsuhashi A; Kakiuchi S; Goto H; Tada H; Nishioka Y
    Nihon Rinsho; 2010 Jun; 68(6):997-1006. PubMed ID: 20535947
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The future of targeted therapies in ovarian cancer.
    Banerjee S; Gore M
    Oncologist; 2009 Jul; 14(7):706-16. PubMed ID: 19592450
    [TBL] [Abstract][Full Text] [Related]  

  • 7. American Society of Clinical Oncology guidance statement: the cost of cancer care.
    Meropol NJ; Schrag D; Smith TJ; Mulvey TM; Langdon RM; Blum D; Ubel PA; Schnipper LE;
    J Clin Oncol; 2009 Aug; 27(23):3868-74. PubMed ID: 19581533
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Clinical cancer research 2001: new agents and therapies.
    Verweij J; de Vries EG
    Drug Resist Updat; 2001 Aug; 4(4):217-23. PubMed ID: 11991676
    [No Abstract]   [Full Text] [Related]  

  • 9. Somatic pharmacogenomics in cancer.
    Ikediobi ON
    Pharmacogenomics J; 2008 Oct; 8(5):305-14. PubMed ID: 18679398
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Targeted cancer therapeutics.
    Hait WN; Hambley TW
    Cancer Res; 2009 Feb; 69(4):1263-7; discussion 1267. PubMed ID: 19208830
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Anthracycline- and/or taxane-resistant breast cancer: results of a literature review to determine the clinical challenges and current treatment trends.
    Moreno-Aspitia A; Perez EA
    Clin Ther; 2009 Aug; 31(8):1619-40. PubMed ID: 19808124
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Front-line drug discovery system for cancer].
    Mizukami T
    Gan To Kagaku Ryoho; 2008 Dec; 35(13):2293-300. PubMed ID: 19098393
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The epothilones: how pharmacology relates to clinical utility.
    Michaud LB
    Ann Pharmacother; 2009 Jul; 43(7):1294-309. PubMed ID: 19584389
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Genetic determinants of anticancer drug activity: towards a global approach to personalized cancer medicine.
    Picker A; Jackson DB
    Expert Rev Mol Diagn; 2011 Jul; 11(6):567-77. PubMed ID: 21745011
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The role of genetic testing in the prediction of response to EGFR inhibitors in NSCLC.
    Hirsch FR
    Oncogene; 2009 Aug; 28 Suppl 1():S1-3. PubMed ID: 19680291
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Targeting cancer stem cells for more effective therapies: Taking out cancer's locomotive engine.
    Winquist RJ; Boucher DM; Wood M; Furey BF
    Biochem Pharmacol; 2009 Aug; 78(4):326-34. PubMed ID: 19539800
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Epigenome-derived drugs: recent advances and future perspectives.
    Vogiatzi P; Aimola P; Scarano MI; Claudio PP
    Drug News Perspect; 2007 Dec; 20(10):627-33. PubMed ID: 18301797
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Bundling next-generation cancer therapies for synergy.
    Kling J
    Nat Biotechnol; 2006 Aug; 24(8):871-2. PubMed ID: 16900109
    [No Abstract]   [Full Text] [Related]  

  • 19. [Target selectivity of anticancer drugs].
    Fattoruso SI; Di Lauro L; Conti F; Amodio A; Lopez M
    Clin Ter; 2008; 159(3):189-206. PubMed ID: 18594750
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Targeted therapies: the answer to individualized treatment?
    Hutchinson L
    Nat Clin Pract Oncol; 2007 Jun; 4(6):323. PubMed ID: 17534387
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 8.